Skip to main content
Log in

Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy

  • Original Paper
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Purpose

The length of neutropenia has a significant impact on the incidence of bloodstream infection (BSI) in cancer patients, but limited information is available about the pathogen distribution in late BSI.

Methods

Between 2002 and 2014, BSI episodes in patients with neutropenia receiving chemotherapy for hematologic malignancies were prospectively identified by multicenter, active surveillance in Germany, Switzerland and Austria. The incidence of first BSI episodes, their microbiology and time to BSI onset during the first episode of neutropenia of 15,988 patients are described.

Results

The incidence rate of BSI episodes was 14.7, 8.7, and 4.7 per 1000 patient-days in the first, second, and third week of neutropenia, respectively. BSI developed after a median of 5 days of neutropenia (interquartile range [IQR] 3–10 days). The medium duration of neutropenia to BSI onset was 4 days in Escherichia coli (IQR 3–7 days), Klebsiella spp. (2–8 days), and Staphylococcus aureus (3–6 days). In contrast, BSI due to Enterococcus faecium occurred after a median of 9 days (IQR 6–14 days; p < 0.001 vs. other BSI). Late onset of BSI (occurring after the first week of neutropenia) was also observed for Stenotrophomonas maltophilia (12 days, IQR 7–17 days; p < 0.001), and non-albicans Candida spp. (13 days, IQR 8–19 days; p < 0.001).

Conclusions

Over the course of neutropenia, the proportion of difficult to treat pathogens such as E. faecium, S. maltophilia, and Candida spp. increased. Among other factors, prior duration of neutropenia may help to guide empiric antimicrobial treatment in febrile neutropenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transpl. 2009;15:47–53. https://doi.org/10.1016/j.bbmt.2008.10.024.

    Article  CAS  Google Scholar 

  2. Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7:11–7. https://doi.org/10.1111/j.1399-3062.2005.00088.x.

    Article  CAS  PubMed  Google Scholar 

  3. Marin M, Gudiol C, Ardanuy C, Garcia-Vidal C, Jimenez L, Domingo-Domenech E, et al. Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection. Clin Microbiol Infect. 2015;21:583–90. https://doi.org/10.1016/j.cmi.2015.01.029.

    Article  CAS  PubMed  Google Scholar 

  4. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103–10. https://doi.org/10.1086/374339.

    Article  PubMed  Google Scholar 

  5. Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68:321–31. https://doi.org/10.1016/j.jinf.2013.12.006.

    Article  PubMed  Google Scholar 

  6. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–35. https://doi.org/10.3324/haematol.2013.091025.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–31. https://doi.org/10.1093/cid/ciq147.

    Article  PubMed  Google Scholar 

  8. Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53:798–806. https://doi.org/10.1093/cid/cir492.

    Article  PubMed  Google Scholar 

  9. Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: a practical update. Virulence. 2016;7:280–97. https://doi.org/10.1080/21505594.2016.1156821.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:905–14. https://doi.org/10.1093/cid/cis580.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Safdar N, Kluger DM, Maki DG. A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters: implications for preventive strategies. Medicine (Baltimore). 2002;81:466–79.

    Article  PubMed  Google Scholar 

  12. Rosa RG, Goldani LZ, dos Santos RP. Risk factors for multidrug-resistant bacteremia in hospitalized cancer patients with febrile neutropenia: a cohort study. Am J Infect Control. 2014;42:74–6. https://doi.org/10.1016/j.ajic.2013.06.025.

    Article  PubMed  Google Scholar 

  13. Dettenkofer M, Wenzler-Rottele S, Babikir R, Bertz H, Ebner W, Meyer E, et al. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project. Clin Infect Dis. 2005;40:926–31. https://doi.org/10.1086/428046.

    Article  CAS  PubMed  Google Scholar 

  14. Weisser M, Theilacker C, Tschudin Sutter S, Babikir R, Bertz H, Gotting T, et al. Secular trends of bloodstream infections during neutropenia in 15 181 haematopoietic stem cell transplants: 13-year results from a European multicentre surveillance study (ONKO-KISS). Clin Microbiol Infect. 2017;23:854–9. https://doi.org/10.1016/j.cmi.2017.03.020.

    Article  CAS  PubMed  Google Scholar 

  15. Kern WV, Weber S, Dettenkofer M, Kaier K, Bertz H, Behnke M, et al. Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014. J Infect. 2018;77:68–74. https://doi.org/10.1016/j.jinf.2018.05.004.

    Article  PubMed  Google Scholar 

  16. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–32. https://doi.org/10.1016/j.ajic.2008.03.002.

    Article  PubMed  Google Scholar 

  17. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–40.

    Article  CAS  PubMed  Google Scholar 

  18. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2016. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017. https://ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2016. Accessed 26 May 2017.

  19. Meyer E, Beyersmann J, Bertz H, Wenzler-Rottele S, Babikir R, Schumacher M, et al. Risk factor analysis of blood stream infection and pneumonia in neutropenic patients after peripheral blood stem-cell transplantation. Bone Marrow Transpl. 2007;39:173–8. https://doi.org/10.1038/sj.bmt.1705561.

    Article  CAS  Google Scholar 

  20. Hieke S, Bertz H, Dettenkofer M, Schumacher M, Beyersmann J. Initially fewer bloodstream infections for allogeneic vs. autologous stem-cell transplants in neutropenic patients. Epidemiol Infect. 2013;41:158–64. https://doi.org/10.1017/s0950268812000283.

    Article  Google Scholar 

  21. Herbers AH, de Haan AF, van der Velden WJ, Donnelly JP, Blijlevens NM. Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2014;16:279–85. https://doi.org/10.1111/tid.12195.

    Article  CAS  PubMed  Google Scholar 

  22. Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest. 2010;120:4332–41. https://doi.org/10.1172/JCI43918.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, Zhan X, et al. Activation of HIF-1alpha and LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat Med. 2015;21:808–14. https://doi.org/10.1038/nm.3871.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kamboj M, Chung D, Seo SK, Pamer EG, Sepkowitz KA, Jakubowski AA, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transpl. 2010;16:1576–81. https://doi.org/10.1016/j.bbmt.2010.05.008.

    Article  Google Scholar 

  25. Satlin MJ, Soave R, Racanelli AC, Shore TB, van Besien K, Jenkins SG, et al. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014;55:2858–65. https://doi.org/10.3109/10428194.2014.896007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kang Y, Vicente M, Parsad S, Brielmeier B, Pisano J, Landon E, et al. Evaluation of risk factors for vancomycin-resistant Enterococcus bacteremia among previously colonized hematopoietic stem cell transplant patients. Transpl Infect Dis. 2013;15:466–73. https://doi.org/10.1111/tid.12120.

    Article  CAS  PubMed  Google Scholar 

  27. Gudiol C, Ayats J, Camoez M, Dominguez MA, Garcia-Vidal C, Bodro M, et al. Increase in bloodstream infection due to vancomycin-susceptible Enterococcus faecium in cancer patients: risk factors, molecular epidemiology and outcomes. PLoS One. 2013;8:e74734. https://doi.org/10.1371/journal.pone.0074734.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Blennow O, Ljungman P, Sparrelid E, Mattsson J, Remberger M. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transpl Infect Dis. 2014;16:106–14. https://doi.org/10.1111/tid.12175.

    Article  CAS  PubMed  Google Scholar 

  29. Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection. 2010;38:211–5. https://doi.org/10.1007/s15010-010-0023-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309–16. https://doi.org/10.1086/315193.

    Article  CAS  PubMed  Google Scholar 

  31. Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother. 2009;53:5026–34. https://doi.org/10.1128/AAC.01031-09.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Gamaletsou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgarelis M, et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20:O50–7. https://doi.org/10.1111/1469-0691.12312.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Dr. Maja Weisser and Dr. Nina Khanna for their help in infection documentation and data analysis. We also would like to thank Regina Babikir, Winfried Ebner for their support in managing the study and data collection. In addition, we would like to thank the medical staff and study nurses at all the participating centers for the invaluable support they provided to the studies over the years. This study has been presented in part at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, the Netherlands.The study was supported in part with funds from the German Federal Ministry of Health.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Andreas F. Widmer.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 54 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Widmer, A.F., Kern, W.V., Roth, J.A. et al. Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy. Infection 47, 837–845 (2019). https://doi.org/10.1007/s15010-019-01327-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-019-01327-0

Keywords

Navigation